Compare KREF & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | ALEC |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.4M | 275.8M |
| IPO Year | 2015 | 2019 |
| Metric | KREF | ALEC |
|---|---|---|
| Price | $5.40 | $2.49 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $7.00 | $3.90 |
| AVG Volume (30 Days) | 924.6K | ★ 2.0M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $349.17 | $900.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.52 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.94 | $1.09 |
| 52 Week High | $9.11 | $2.84 |
| Indicator | KREF | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 61.48 |
| Support Level | $5.09 | $1.90 |
| Resistance Level | $6.01 | $2.65 |
| Average True Range (ATR) | 0.34 | 0.23 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 42.60 | 64.22 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.